GenEditBio Receives FDA Clearance for First-in-Class CRISPR Gene Therapy Trial in TGFBI Corneal Dystrophy
核心洞察
GenEditBio (搜索) received FDA clearance for its IND application to initiate Phase 1/2 CLARITY trial for GEB-101 (搜索), a first-in-class genome-editing therapy targeting TGFBI corneal dystrophy (搜索).
The trial will evaluate safety, tolerability and efficacy of GEB-101 (搜索) delivered via single intrastromal injection using the company's proprietary ribonucleoprotein-based CRISPR technology.
Current treatment options for TGFBI corneal dystrophy (搜索) are limited and do not address the underlying genetic cause, creating significant unmet medical need.
GenEditBio (搜索) Limited, a clinical-stage biotechnology startup, announced that the U.S. Food and Drug Administration has cleared the company's Investigational New Drug application to initiate Phase 1/2 CLARITY trial activities for its lead in vivo genome-editing program GEB-101 (搜索) for TGFBI corneal dystrophy (搜索). The regulatory milestone enables the Hong Kong-based company to advance its first-in-class genome-editing therapy into human testing.
Novel CRISPR Approach for Genetic Eye Disease
GEB-101 (搜索) represents a first-in-class investigational genome-editing therapy designed as a one-and-done treatment for TGFBI corneal dystrophy (搜索). The therapy is based on CRISPR-Cas genome-editing technology that targets a particular locus in the mutated TGFBI (搜索) gene. The treatment is encapsulated in the form of ribonucleoprotein in an engineered protein delivery vehicle, a proprietary in vivo delivery system developed by GenEditBio (搜索).
"GEB-101 (搜索) is a first-in-class investigational genome-editing therapy for TGFBI corneal dystrophy (搜索). Current treatment options are limited and do not address the underlying cause, highlighting a significant unmet need for a targeted genetic approach," said Tian ZHU, PhD, CEO and Co-Founder of GenEditBio (搜索).
CLARITY Trial Design and Timeline
The Phase 1/2 CLARITY trial will collect initial data on the safety, tolerability and efficacy of GEB-101 (搜索) in corneal dystrophy patients with TGFBI (搜索) mutation. The study features a seamless, adaptive, multicenter, sequential design. Trial participants will receive a single intrastromal injection of GEB-101. Patient enrollment is expected to commence in the second quarter of this year after site activation in the U.S.
The company plans to expand the CLARITY trial through regulatory clearance in other major markets following the U.S. trial initiation.
Addressing Significant Unmet Medical Need
TGFBI corneal dystrophy (搜索) is a group of genetic eye disorders caused by mutations in the TGFBI (搜索) gene, resulting in progressive abnormal protein buildup and deposits in the cornea. Symptoms include photophobia (搜索), gradual vision loss (搜索) and recurrent corneal erosions (搜索) with debilitating pain, impacting patients' long-term quality of life.
Current treatment options include phototherapeutic keratectomy and corneal transplantation. Both procedures have known limitations such as high rates of recurrence and the risk of sight-threatening complications, underscoring the urgent need for novel therapies.
Company Leadership Perspective
"This regulatory IND clearance for our lead clinical asset, GEB-101 (搜索), marks a momentous milestone in our commitment towards bringing transformative ribonucleoprotein-based, ready-to-act and rapid degradation editor for one-and-done in vivo genome-editing therapy with high target tissue editing and low off-target editing risk to patients globally," said Zongli ZHENG, PhD, Chairman and Co-Founder of GenEditBio (搜索).
The IND clearance validates the company's robust preclinical data on safety and efficacy, according to company leadership. GEB-101 (搜索) is currently being investigated for safety and preliminary efficacy in an investigator-initiated trial in China.
About GenEditBio
Established in 2021 and headquartered in Hong Kong, GenEditBio (搜索) is a clinical-stage gene therapy startup focused on providing in vivo genome-editing therapeutic solutions for genetic diseases with unmet needs. The company's core areas of focus include novel Cas nuclease discovery and safe and efficient cargo delivery utilizing lipid nanoparticle and engineered protein delivery vehicle technologies. GenEditBio maintains research laboratories and supporting offices in Hong Kong, Beijing, and Boston, with financial backing from top-tier life science investors including Qiming Venture Partners, Fangyuan Capital, Center Biotherapeutics, Lumosa Therapeutics, and HKSTP Venture Fund.